Vanguard Group Inc. raised its holdings in shares of Zafgen, Inc. (NASDAQ:ZFGN) by 15.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 883,838 shares of the biopharmaceutical company’s stock after purchasing an additional 119,902 shares during the period. Vanguard Group Inc. owned 3.23% of Zafgen worth $3,102,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Algert Global LLC acquired a new position in Zafgen during the 2nd quarter valued at about $123,000. Parametric Portfolio Associates LLC lifted its position in Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 10,327 shares during the period. GSA Capital Partners LLP acquired a new position in Zafgen during the 2nd quarter valued at about $259,000. LMR Partners LLP acquired a new position in Zafgen during the 2nd quarter valued at about $299,000. Finally, Acadian Asset Management LLC acquired a new position in Zafgen during the 2nd quarter valued at about $304,000. Institutional investors own 48.70% of the company’s stock.

Shares of Zafgen, Inc. (ZFGN) opened at $3.87 on Tuesday. Zafgen, Inc. has a 52 week low of $3.11 and a 52 week high of $5.46.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.12. analysts expect that Zafgen, Inc. will post -2.02 EPS for the current fiscal year.

ZFGN has been the topic of a number of research reports. ValuEngine downgraded shares of Zafgen from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 10th. Zacks Investment Research downgraded shares of Zafgen from a “buy” rating to a “hold” rating in a research report on Saturday, September 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $6.63.

In related news, Director Frances K. Heller purchased 10,000 shares of the stock in a transaction dated Friday, October 13th. The stock was bought at an average cost of $3.90 per share, with a total value of $39,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 21.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/vanguard-group-inc-grows-holdings-in-zafgen-inc-zfgn/1744953.html.

Zafgen Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.